You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Development of a novel highly effective influenza vaccine

    SBC: FLUGEN INC            Topic: NIAID

    DESCRIPTION provided by applicant Seasonal influenza flu virus an NIAID category C priority pathogen causes widespread infection resulting in at least million cases of severe illness and deaths worldwide Young children and elderly or immunocompromised individuals are typically at greater risk of severe illness or death from influenza Newly emerging strains can result ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. Development of Peptide Antibiotic Nucleic Acids

    SBC: NUBAD LLC            Topic: NIAID

    DESCRIPTION provided by applicant One of the challenges of research in infectious diseases is to find ways to use the increasing knowledge of the mechanisms underlying disease transformation and progression to develop novel therapeutic strategies for diseases such as increasing menace of bacterial infections Targeting specific RNA such as rRNA which are involved in proliferation and survival ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. STTR Phase I: 24x7 mobile wireless monitoring of patient's vitals to proactively manage disease recovery

    SBC: Argosy Omnimedia, Inc.            Topic: SH

    The broader impact/commercial potential of this Small Business Technology Transfer (STTR) Phase I project is found in the proposed technology development that facilitates direct, ubiquitous acquisition of key biomedical data, with little or no human intervention or introduction of errors, has the potential to reduce the costs of healthcare and to revolutionize healthcare delivery throughout our so ...

    STTR Phase I 2014 National Science Foundation
  4. STTR Phase I: Investigating Self-powered Health Monitoring of Orthopedic Implants and Data Retrieval Using Diagnostic Ultrasound

    SBC: Piezonix LLC            Topic: SH

    The broader impact/commercial potential of this Small Business Technology Transfer (STTR) Phase I project will be a significant transformation-changing reactive orthopedic surgery into proactive, preventive and cost-effective surgery. The project will have a direct positive impact on the quality of orthopedic surgery practice while reducing significant social costs. According to 2013 national surv ...

    STTR Phase I 2014 National Science Foundation
  5. STTR Phase I: Handheld Open Source Photometer as enabling tool for Enzyme-based analytical chemistry

    SBC: NITRATE ELIMINATION CO INC            Topic: CT

    The broader impact/commercial potential of this project is to make chemistry more accessible by developing a rugged, compact, LED-based photometer that communicates data to other devices via Bluetooth. The photometer and data processing functions will be designed to work with the company?s simplified test kits for Green Analytical Chemistry. The photometer will be sold at just above cost, estimate ...

    STTR Phase I 2014 National Science Foundation
  6. STTR Phase I: Rapid Blood Typing with a Portable Medical Device

    SBC: Microdevice Engineering, Inc.            Topic: BM

    The broader impact/commercial potential of this Small Business Technology Transfer (STTR) Phase I project is the creation of a faster, more portable, affordable and reliable blood typing and red blood cell concentration test. This is important because trauma centers and hospitals rely extensively on blood donations provided by blood banks across the U.S. to save lives. There are currently 84 milli ...

    STTR Phase I 2014 National Science Foundation
  7. STTR Phase I: Ferrofluidic enclosures for enhanced control of thermal and magnetic fields in spin-stabilized atomic micro-devices

    SBC: COMMET LLC            Topic: EW

    The broader impact/commercial potential of this project is determined by new consumer products and new industries which would flourish on portable and reliable atomic clocks, gyroscopes, and magnetometers when they become available. Proposed compact thermal and magnetic enclosure reduces the most bulky part of such devices and provides an avenue for further miniaturization. A chip-scale atomic clo ...

    STTR Phase I 2014 National Science Foundation
  8. STTR Phase I: MEMS Reconfigurable Antenna for Portable Wireless Devices

    SBC: Black Hills Nanosystems            Topic: EW

    The broader impact/commercial potential of this project is the commercial availability of the reconfigurable antenna product for the mobile market. The reconfigurable antenna can provide enormous benefits including power savings, improve signal reception, bandwidth, link budgets, reduce drop-calls and improve overall call quality, improved gain/range and increasing the number of devices served by ...

    STTR Phase I 2014 National Science Foundation
  9. Development of VPL Vaccine for RSV

    SBC: SIGMOVIR BIOSYSTEMS, INC.            Topic: NIAID

    Project Summary Human respiratory syncytial virus (RSV) is recognized as the single most important viral cause of acute respiratory disease in infants and young children worldwide. Elderly populations and immunocompromised individuals are also at significant risk for serious RSV disease. Despite this very substantial disease burden imposed by RSV worldwide, there are no vaccines available. Severa ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. An innovative in situ cell reprogramming technology for cancer treatment

    SBC: QURGEN, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): We invented an innovative protein induced Pluripotent Stem Cells (piPSCs) technology that generates piPSCs from normal fibroblast and cancer cells within 1-week with 90 4% conversion efficiency. Such high conversion efficiency enables us to pioneer an in situ cell reprogramming technology within the cancers of cancer-bearing animals. Instead of generating iPSCs ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government